Oberhoff M, Herdeg C, Baumbach A, Shamet K, Kranzhöfer A, Weingärtner O, Rübsamen K, Kluge M, Karsch K R
Department of Medicine, University of Tübingen, Germany.
Cathet Cardiovasc Diagn. 1997 Jul;41(3):268-74. doi: 10.1002/(sici)1097-0304(199707)41:3<268::aid-ccd7>3.0.co;2-4.
It has been reported previously that systemic application of low molecular weight heparin (LMWH) suppresses smooth muscle cell (SMC) proliferation after balloon angioplasty in experimental studies. However, the high concentration of heparin required for a beneficial effect may cause severe bleeding complications. The ideal situation to overcome the systemic side effects would be to administer LMWH locally and deep into the arterial wall, which became possible by the development of porous balloon catheters. The in vivo feasibility of local delivery of LMWH using the porous balloon has been assessed by delivering tritium-marked LMWH into rabbit carotid arteries. The efficacy of the system was investigated by using a second injury animal model. After development of an intimal plaque by electrical stimulation, 61 rabbits were treated with the porous balloon after balloon angioplasty. In 23 rabbits, local drug delivery was accomplished with a porous balloon catheter (35 holes, hole diameter 75 microns, 2.5 mm catheter diameter). LMWH was locally administered with 4 ml (solution 375 anti-Xa-units/ml) and 2 atm. To study the extent of restenosis and morphological changes, these animals were killed 3, 7, 14, 28, or 56 d after intervention. After staining (hematoxylin, van Gieson, BrdU, RAM 11, alpha-actin) procedures to quantify SMC proliferation, intimal macrophages and morphological analysis were performed. Porous balloon treatment led to an increase in intimal SMC proliferation rate in the early stage after intervention. However, during the following time period, a significant decrease of the proliferation rate as compared with the animals treated with balloon angioplasty alone could be observed, which resulted in an only moderate increase of the intimal layer after local drug delivery compared with balloon angioplasty alone.
先前已有报道称,在实验研究中,全身应用低分子量肝素(LMWH)可抑制球囊血管成形术后平滑肌细胞(SMC)的增殖。然而,产生有益效果所需的高浓度肝素可能会导致严重的出血并发症。克服全身副作用的理想情况是将LMWH局部且深入地注入动脉壁,而多孔球囊导管的研发使这成为可能。通过将氚标记的LMWH注入兔颈动脉,评估了使用多孔球囊局部递送LMWH在体内的可行性。通过使用二次损伤动物模型研究了该系统的疗效。在通过电刺激形成内膜斑块后,61只兔子在球囊血管成形术后接受了多孔球囊治疗。在23只兔子中,使用多孔球囊导管(35个孔,孔径75微米,导管直径2.5毫米)完成局部药物递送。LMWH以4毫升(溶液375抗Xa单位/毫升)和2个大气压进行局部给药。为了研究再狭窄程度和形态学变化,在干预后3、7、14、28或56天处死这些动物。在进行染色(苏木精、范吉森、BrdU、RAM 11、α-肌动蛋白)程序以量化SMC增殖后,进行内膜巨噬细胞和形态学分析。多孔球囊治疗在干预后的早期导致内膜SMC增殖率增加。然而,在随后的时间段内,与仅接受球囊血管成形术治疗的动物相比,可观察到增殖率显著降低,这导致与仅接受球囊血管成形术相比,局部药物递送后内膜层仅适度增加。